Tenofovir alafenamide clinical trials
Also written Vemlidy, TAF and GS-7340.
Related medicines add 2 studies
Counted the way a researcher would: Tenofovir alafenamide with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses tenofovir alafenamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tenofovir alafenamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 5 Nov 2015 · GENVOYA · NDA 207561 (FDA, Drugs@FDA; in a combination)
- European Union
- 19 Nov 2015 · Genvoya · EMEA/H/C/004042 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
140 studies that test it; most in 2021 (17)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 8 |
| 2014 | 5 |
| 2015 | 14 |
| 2016 | 11 |
| 2017 | 9 |
| 2018 | 12 |
| 2019 | 15 |
| 2020 | 14 |
| 2021 | 17 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 62 · Other 78
Gilead Sciences (49) · Third Affiliated Hospital, Sun Yat-Sen University (6) · Janssen Sciences Ireland UC (3) · Young-Suk Lim (2) · Taichung Veterans General Hospital (2) · National Taiwan University Hospital (2) · Fundacion SEIMC-GESIDA (2) · The Third Affiliated Hospital of Guangzhou Medical University (2)
Often tested with
Tested in the same studies.
Emtricitabine (68) · Bictegravir (33) · Cobicistat (28) · Elvitegravir (20) · Darunavir (13) · Dolutegravir (7) · Lenacapavir (5) · Emtricitabine tenofovir alafenamide (5)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 8 phase 3 studies under way
Tenofovir alafenamide is the comparator. A study of two new drugs counts under both.
- 3Islatravir · Merck Sharp & Dohme LLC · next primary completion Feb 2029
- 2Lamivudine · ViiV Healthcare, José Antonio Mata Marín
- 1Bictegravir · Gilead Sciences
- 1Lenacapavir · Gilead Sciences
- 1Dolutegravir · ViiV Healthcare
- 1Lepetegravir · Gilead Sciences · next primary completion Jan 2028
- 1Ulonivirine · Merck Sharp & Dohme LLC · next primary completion Feb 2029
- 1Azvudine · Zhigang Ren · next primary completion Dec 2026
Reaching primary completion within a year · 8, 1 in phase 3
Studies that test tenofovir alafenamide, phase 3 first.
- Jun 2027A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis BPhase 2/3 · Xi'an Xintong Pharmaceutical Research Co.,Ltd.
- Dec 2026Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral TreatmentPhase 4 · Yonsei University
- Jan 2027Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy VolunteersPhase 1 · Johns Hopkins University
- Mar 2027TAF in Early/Middle Pregnancy With CHBPhase 4 · The Third Affiliated Hospital of Guangzhou Medical University
- Jun 2027A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsPhase 4 · Gilead Sciences
- Jun 2027REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidEPhase 4 · CAN Community Health
- Aug 2027A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1Phase 2 · Gilead Sciences
- Sep 2027TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular CarcinomaNot applicable · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses tenofovir alafenamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 140
- Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized StudyRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05652478Written as Dolutegravir (DTG) AND Tenofovir alafenamide (TAF)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidERecruitingPhase 4CAN Community HealthNCT07476339Written as Bictegravir, emtricitabine, and tenofovir alafenamide
- Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)RecruitingPhase 4Jidong JiaNCT04939441Written as Tenofovir alafenamide
- A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1RecruitingPhase 2Gilead SciencesNCT07645287Written as B/F/TAF
- Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 TreatmentRecruitingPhase 2/3Gilead SciencesNCT07708727Written as B/F/TAF
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as F/TAF (Low Dose Tablet)
- TAF vs TDF During the PregancyEnrolling by invitationPhase 4The Third Affiliated Hospital of Guangzhou Medical UniversityNCT07542951Written as TAF
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Tenofovir alafenamide (TAF)
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Triple therapy: darunavir/cobicistat plus tenofovir alafenamide/emtricitabine
- TAF in Early/Middle Pregnancy With CHBEnrolling by invitationPhase 4The Third Affiliated Hospital of Guangzhou Medical UniversityNCT07668934Written as TAF
- Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis BRecruitingPhase 4Taichung Veterans General HospitalNCT03933384Written as Tenofovir alafenamide
- Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy VolunteersRecruitingPhase 1Johns Hopkins UniversityNCT07349758Written as tenofovir alafenamide [TAF] 50 mg/emtricitabine [FTC] 400mg
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort ApproachNot yet recruitingPhase 4The Task Force for Global HealthNCT07258251Written as Tenofovir Alafenamide (TAF)
- TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular CarcinomaNot yet recruitingNot applicableSun Yat-sen UniversityNCT07253220Written as TAF monotherapy
- Study of Tenofovir Alafenamide in HBV-Infected Pregnant WomenRecruitingPhase 4First People's Hospital of HangzhouNCT05853718Written as Tenofovir Alafenamide Tablets
- Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral LoadsRecruitingNot applicableGuangzhou 8th People's HospitalNCT06947356Written as TAF group
- To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant PatientsNot yet recruitingPhase 2Jongman KimNCT06589518Written as Tenofovir Alafenamide Citrate
- Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLFRecruitingNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT03920618Written as Tenofovir Alafenamide
- The Antiretroviral Speed Access Program Switch (ASAP-Switch) StudyNot yet recruitingPhase 4McGill University Health Centre/Research Institute of the McGill University Health CentreNCT06375304Written as B/F/TAF
- Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.RecruitingNot applicableThird Affiliated Hospital, Sun Yat-Sen UniversityNCT04231565Written as Tenofovir alafenamide Fumarate
See all 140 studies that test tenofovir alafenamide →
Given beside what is tested · 39 — tenofovir alafenamide is usual care or a partner of the new treatment
- People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for EffectivenessNot yet recruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07939529Written as Bictegravir/Emtricitabine/Tenofovir Alafenamide
- Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor ResponseNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07797231Written as Tenofovir Alafenamide Fumarate Tablets
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)RecruitingPhase 2The Second Affiliated Hospital of Chongqing Medical UniversityNCT07852091Written as ETV/TDF/TAF
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)RecruitingPhase 2The Second Affiliated Hospital of Chongqing Medical UniversityNCT05769816Written as NAs
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)RecruitingPhase 2The Second Affiliated Hospital of Chongqing Medical UniversityNCT05771402Written as NAs
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT07711223Written as ACC017+FTC/TAF
- Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical ResectionNot yet recruitingEarly Phase 1Ningbo No.2 HospitalNCT07553767Written as TAF
- Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB PatientsRecruitingNot applicableBeijing 302 HospitalNCT06457477Written as NAs
- A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-InfectionNot yet recruitingPhase 2National Taiwan University HospitalNCT05467553Written as Tenofovir Alafenamide
- A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus InfectionCompletedPhase 2Huahui HealthNCT05861674Written as TAF
- Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult ParticipantsCompletedPhase 1Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06278389Written as Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
- Phase Ib/IIa Clinical Study of ACC017 TabletsCompletedPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT06719310Written as ACC017+FTC/TAF
- A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D VirusCompletedPhase 2Janssen Research & Development, LLCNCT04535544Written as Tenofovir alafenamide (TAF)
- Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIVActive, not recruitingPhase 2Gilead SciencesNCT05052996Written as B/F/TAF
- Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)CompletedPhase 2Gilead SciencesNCT04891770Written as Tenofovir Alafenamide
- Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2-Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing RegimenCompletedPhase 2/3Gilead SciencesNCT02285114Written as F/TAF
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04439539Written as Tenofovir alafenamide
- A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 1Janssen Research & Development, LLCNCT05123599Written as TAF
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04585789Written as Tenofovir alafenamide (TAF)
- Study of Novel Antiretrovirals in Participants With HIV-1CompletedPhase 1Gilead SciencesNCT05585307Written as B/F/TAF
Showing 20 of 39.
As the comparator · 22 — what is tested is compared with tenofovir alafenamide
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07266831Written as BIC/FTC/TAF
- Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus LevelsRecruitingPhase 2Gilead SciencesNCT07841990Written as B/F/TAF
- Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus Type 1 (HIV-1)RecruitingPhase 1/2Jiangsu Aidea Pharmaceutical Group Co., Ltd.NCT07711223Written as ACC017+FTC/TAF
- A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis BRecruitingPhase 3Zhigang RenNCT07307586Written as TAF
- DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityRecruitingPhase 3José Antonio Mata MarínNCT07075146Written as BIC/FTC/TAF
- Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral ExperienceRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07031063Written as Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With BiktarvyActive, not recruitingPhase 3Gilead SciencesNCT06333808Written as B/F/TAF
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyActive, not recruitingPhase 3ViiV HealthcareNCT05979311Written as Tenofovir alafenamide
- DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05705349Written as BIC/FTC/TAF
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)CompletedPhase 3Merck Sharp & Dohme LLCNCT04233879Written as BIC/FTC/TAF
- Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedActive, not recruitingPhase 2/3Gilead SciencesNCT06544733Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been TreatedTerminatedPhase 2/3Gilead SciencesNCT06613685Written as Bictegravir/emtricitabine/tenofovir alafenamide
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT04223791Written as BIC/FTC/TAF
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB PatientsActive, not recruitingNot applicableBeijing 302 HospitalNCT06357806Written as NAs
- Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]CompletedPhase 2Merck Sharp & Dohme LLCNCT04564547Written as BIC/FTC/TAF
- A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT05630755Written as BIC/FTC/TAF
- A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06891066Written as BIC/FTC/TAF
- Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir AlafenamideCompletedPhase 4Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT04636437Written as Tenofovir alafenamide/emtricitabine
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight GainCompletedPhase 4Janssen Scientific Affairs, LLCNCT04442737Written as D/C/F/TAF FDC
- Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis BCompletedPhase 1Nucorion Pharmaceuticals, Inc.NCT04629976Written as Tenofovir Alafenamide 25 mg
Showing 20 of 22.
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)Nov 12, 2026NCT04939441
Codes
What other systems call tenofovir alafenamide · ClinicalTrials.gg INT004405
- MeSH (NLM) C442442tenofovir alafenamideConfirmed NLM, Wikidata
- UNII (FDA) EL9943AG5JTENOFOVIR ALAFENAMIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1721603Confirmed FDA, Wikidata
- Wikidata Q22075912tenofovir alafenamideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C148276Tenofovir AlafenamideOne source FDA
- DrugBank DB09299One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C442442 | tenofovir alafenamide | Confirmed NLM, Wikidata |
| UNII (FDA) | EL9943AG5J | TENOFOVIR ALAFENAMIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1721603 | — | Confirmed FDA, Wikidata |
| Wikidata | Q22075912 | tenofovir alafenamide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C148276 | Tenofovir Alafenamide | One source FDA |
| DrugBank | DB09299 | — | One source Wikidata |
Also registered as tenofovir alafenamide fumarate (UNII FWF6Q91TZO · RxNorm 1721604).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.